For treating paroxysmal nocturnal haemoglobinuria

Rationale 1,6

NICE Guidance

Review Date: 01/10/2025

Renal anaemia or anaemia associated with chemotherapy

Brand: Aranesp

Rationale: 1,2,3,8

NICE TA323

1.1 Erythropoiesis stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.

1.2 If different erythropoiesis stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.

November 2014

Use as monotherapy for the treatment of adult and paediatric patients aged ≥12 years with a weight ≥40kg with paroxysmal nocturnal haemoglobinuria, in patients with haemolysis with clinical symptom(s) indicative of high disease activity, and in patients who are clinically stable after having been treated with a complement component 5 inhibitor for at least the past 6 months

Brand: Piasky®

Rationale 1,6

NICE TA 1019

In line with positive NICE TAs 

Rationale 1,6

Review Date: 01/11/2025

Renal anaemia or anaemia associated with chemotherapy

Brand: NeoRecormon

Rationale: 1,2,4,8

Drug Safety Update
Epoetin beta (NeoRecormon): increased risk of retinopathy in preterm infants cannot be excluded. Further information at:https://www.gov.uk/drug-safety-update/epoetin-beta-neorecormon-increased-risk-of-retinopathy-in-preterm-infants-cannot-be-excluded
May 2015
----------------
NICE TA323

1.1 Erythropoiesis stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.

1.2 If different erythropoiesis stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.

 November 2014

Review Date: 01/11/2025

Anaemia in adults with chronic renal failure or receiving cancer chemotherapy

Rationale: 1,2

Brands: Silapo, Retacrit

NICE NG8
Anaemia management in people with chronic kidney disease
June 2015

Use as monotherapy in the treatment of adults with paroxysmal nocturnal haemoglobinuria who have haemolytic anaemia

Brand : Fabhalta®

Rationale 1,6

NICE Guidance

Review Date: 01/10/2026

Anaemia associated with CKD

Brand:Mircera

Rationale:1,2

NICE NG8 click here
Anaemia management in people with chronic kidney disease, full guidance at: 
June 2015

For treating paroxysmal nocturnal haemoglobinuria

Rationale 1,6

Review Date: 01/01/2027

Anaemia associated with chronic kidney disease

Brand : Evrenzo

Rationale 1,2

NHS England commissioned - Specialist Centre Only

NICE TA807 Roxadustat for treating symptomatic anaemia in chronic kidney disease

There is a simple discount patient access scheme for roxadustat. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact commercial@astellas.com for details.

For treating haemolytic anaemia caused by sickle cell disease

Rationale 1,6

Severe aplastic anaemia (SAA)

Brand : Revolade

Rationale 2

NICE Guidance

Generalised myasthenia gravis

AQP4 antibody-positive neuromyelitis optica spectrum disorder

Rationale 6